( - 78 Percent of Patients Showed Complet...)Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia,Health

SAN DIEGO, CA, March 05, 2007 /PRNewswire-FirstCall/ - Nventa Biopharmaceuticals Corporation today announced the presentation of positive results from a clinical trial examining the safety and efficacy of pilot process HspE7, an investigational therapeutic vaccine for human papillomavirus (HPV)-related diseases, in women with the highest grade of cervical dysplasia (CIN III). The data from two posters were presented by Mark H. Einstein, M.D., the investigator in the trial and an expert in the field of cervical dysplasia, at the 37th Annual Meeting of the Society of Gynecological Oncologists in San Diego. The trial was conducted by the New York Cancer Consortium (an NCI-sponsored consortium) and the New York Gynecologic Oncology Group (NYGOG).

"This trial may lead to a paradigm shift in how select patients with high-grade CIN are treated," said Mark H. Einstein, M.D. "The administration of HspE7 may be an attractive alternative to surgery for a subset of women with high-grade CIN. Placebo-controlled trials need to be performed to fully determine the treatment efficacy and to identify the appropriate subsets of women who may benefit from HspE7." Dr. Einstein is Director of Clinical Research for the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology & Women's Health at the Montefiore Medical Center at Albert Einstein College of Medicine.

Gregory M. McKee, President and Chief Executive Officer of Nventa commented on the study: "The data from this cervical dysplasia trial are consistent with other data in this indication that we have obtained from previous HspE7 trials. We are advancing a new formulation of HspE7 which has been shown to be more potent in preclinical testing and that may produce better results in future clinical trials. We expect to commence a Phase I bri
'"/>